Tumor immunotherapy has emerged as a highly esteemed and rapidly evolving field in recent years, marked by the development of numerous significant therapeutic approaches. Among these, immune checkpoint inhibitors stand out as a pivotal strategy, attracting considerable attention due to their substantial research progress. This article provides a comprehensive review of the current research advancements in ten key immune checkpoints related to anti?tumor therapy, including PD?1/PD?L1, CTLA?4, LAG?3, TIM?3, TIGIT, and VISTA. By conducting an in?depth analysis of their mechanisms of action, clinical applications, and future research directions, this review aims to offer valuable insights and guidance for optimizing strategies in tumor immunotherapy.